A private oncology shared savings plan reduced colon cancer treatment costs. Results varied by tumor, with none in breast cancer and mixed effects in lung cancer.

Tirzepatide injections in box | Image credit: MKPhoto – stock.adobe.com

Real-World Use of GLP-1s Yields Less Weight Loss Than Clinical Trials

By Hayden E. Klein

June 10th 2025

Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically meaningful weight loss and improved glycemic control.

On-body delivery system | Image credit: Enable Injections

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

By Mary Caffrey

June 6th 2025

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

The overall response rate with first-line zanubrutinib for CLL reached 97.3%, with 18.2% of patients experiencing complete response or complete response with incomplete hematologic recovery. | Image Credit: jarun011 - stock.adobe.com

Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial

By Rose McNulty

June 6th 2025

Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.

Factors That Increase Utilization Management Risk: A Proof of Concept

By Jason Shafrin, PhD
Jacob Fajnor, BA

Shurui Zhang, MS
Donald E. Nichols, PhD

June 3rd 2025

A score was developed to measure patient risk from payer utilization management policies and its relationship to real-world US commercial payer utilization management policies.

...

38 39 40 41 42

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions